vTv Therapeutics Inc. (VTVT) revenue
vTv Therapeutics Inc. (VTVT) reported revenue of $1.02M in fiscal 2024 (the year ended December 31, 2024). Figures as of 18 Nov 2026, 12:08 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2024
- $1.02M
- Growth, 5 years
- −18.1% a year
- Growth, 10 years
- −4.1% a year
- Highest on record
- $12.43Mfiscal 2018
- Lowest on record
- $291.00Kfiscal 2017
- Fiscal years on record
- 112013–2024
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
vTv Therapeutics Inc. revenue, in more detail
Over the five fiscal years to 2024 revenue shrank at a compound 18.1% a year; over ten years the rate was −4.1% a year. Across the 11 fiscal years on record (2013–2024), the highest was $12.43M in fiscal 2018 and the lowest $291.00K in fiscal 2017.
Revenue by fiscal year
vTv Therapeutics Inc. revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2024 | $1.02M | — | |
| 2022 | $2.02M | 49.6% down | |
| 2021 | $4.01M | 37.6% down | |
| 2020 | $6.41M | 132.1% up | |
| 2019 | $2.76M | 77.8% down | |
| 2018 | $12.43M | 4,172.9% up | |
| 2017 | $291.00K | 54.1% down | |
| 2016 | $634.00K | 22.2% up | |
| 2015 | $519.00K | 66.5% down | |
| 2014 | $1.55M | 58.7% up | |
| 2013 | $976.00K | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
vTv Therapeutics Inc., figure by figure
- vTv Therapeutics Inc. market cap
- vTv Therapeutics Inc. earnings
- vTv Therapeutics Inc. earnings per share (EPS)
- vTv Therapeutics Inc. P/E ratio
- vTv Therapeutics Inc. P/S ratio
- vTv Therapeutics Inc. P/B ratio
- vTv Therapeutics Inc. free cash flow
- vTv Therapeutics Inc. operating margin
- vTv Therapeutics Inc. dividend
- vTv Therapeutics Inc. shares outstanding
- vTv Therapeutics Inc. total debt
- vTv Therapeutics Inc. cash on hand
- vTv Therapeutics Inc. total assets
- vTv Therapeutics Inc. return on equity (ROE)
- vTv Therapeutics Inc. return on invested capital (ROIC)
vTv Therapeutics Inc. (VTVT) overview: price, valuation and scorecard
vTv Therapeutics Inc. revenue: questions and answers
What is vTv Therapeutics Inc.'s revenue?
vTv Therapeutics Inc. (VTVT) reported revenue of $1.02M in fiscal 2024 (the year ended December 31, 2024).
What is the growth rate of vTv Therapeutics Inc.'s revenue?
Over the five fiscal years to 2024 revenue shrank at a compound 18.1% a year; over ten years the rate was −4.1% a year.
What are the highest and lowest revenue figures on record for vTv Therapeutics Inc.?
Across the 11 fiscal years on record (2013–2024), the highest was $12.43M in fiscal 2018 and the lowest $291.00K in fiscal 2017.
How is vTv Therapeutics Inc.'s revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For vTv Therapeutics Inc. it is on record here for 11 fiscal years, 2013 to 2024.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “vTv Therapeutics Inc. (VTVT) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/VTVT/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.